1.
Ann Card Anaesth
;
2014 Apr; 17(2): 173-174
Article
in English
| IMSEAR
| ID: sea-150324
Subject(s)
Administration, Oral , Aged , Angioedema/chemically induced , Angioedema/diagnosis , Angioedema/etiology , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Female , Humans , Morpholines/administration & dosage , Morpholines/adverse effects , Thiophenes/administration & dosage , Thiophenes/adverse effects
2.
Indian J Med Sci
;
2010 Nov; 64(11) 520-528
Article
in English
| IMSEAR
| ID: sea-145574
ABSTRACT
For more than 50 years, warfarin has single-handedly ruled the world of anti-coagulation without any competition, whatsoever! The anticoagulant was made available in 1940 and since then no other anti-coagulant has ever been able to match it in the clinical arena. But it looks like that the advances in the field of anti-coagulation, for the first time, have seriously started to erode its base. This review takes a look at rivaroxaban, a direct factor Xa inhibitor and one of the most foremost competitors of warfarin.
Subject(s)
Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Anticoagulants/pharmacokinetics , Biological Availability , Blood Coagulation/drug effects , Cardiovascular Diseases/blood , Cardiovascular Diseases/drug therapy , Drug Monitoring/methods , Factor Xa/antagonists & inhibitors , Humans , Morpholines/administration & dosage , Morpholines/adverse effects , Morpholines/pharmacokinetics , Outcome Assessment, Health Care , Pharmacovigilance , Thiophenes/administration & dosage , Thiophenes/adverse effects , Thiophenes/pharmacokinetics
3.
São Paulo med. j
;
127(6): 385-386, Nov. 2009.
Article
in English
| LILACS
| ID: lil-547349
Subject(s)
Female , Humans , Antiemetics/adverse effects , Antineoplastic Agents, Alkylating/therapeutic use , Cyclophosphamide/therapeutic use , Morpholines/adverse effects , Receptors, Neurokinin-1/antagonists & inhibitors , Antiemetics/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/ethnology , Breast Neoplasms/metabolism , Cyclophosphamide/analogs & derivatives , Cyclophosphamide/metabolism , Drug Interactions , Morpholines/therapeutic use
4.
Article
in English
| IMSEAR
| ID: sea-91991